Generic drugmakers Teva and Glenmark recently became the sixth and seventh drugmakers to resolve criminal charges as a result of the DOJ’s yearslong investigation into generic drug price fixing. The settlement agreement requires both companies to pay hefty fines as well as divest their drug lines for pravastatin, a widely used statin that lowers cholesterol.
When is a skinny label skinny enough to protect a generic drug from claims of patent infringement? The answer remains up to interpretation after an important, controversial decision from the Federal Circuit.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It seems there's no longer any tolerance for the 'how far can we push this' approach. The smart players are instead asking 'what is reasonable and sustainable in our current healthcare climate?'
Check out Friday's MedHeads and catch up on the top stories of the week.
This investment will help pharma giant Teva "expand its solutions beyond medication," CEO Erez Vigodman said.
Teva started its bid for Mylan on Tuesday. They are confident - even though Myland said "no thanks" back on Friday. Read about this, the latest stats on investing in medical startups and more in The Morning Read.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Israeli drugmaker Teva Pharmaceuticals and the healthcare arm of Netherlands-based Royal Philips have launched a new health tech incubator in Israel called Sanara Ventures – investing more than $25 million in the project over eight years. The incubator’s meant to house and seed startups in the med tech space, according to the Israeli newspaper Globes. It says it’s looking […]